Similar outcomes were observed in NSCLC cell lines intrinsically resistant towards DDR-targeting (Atm) inhibitors, as they express higher levels of Axl compared to sensitive ones [78]. The gene discussed is AXL; the disease is non-small cell lung carcinoma.